Skip to main content
Find a Lawyer

Encyclopedia of Law & Economics – 5880 Pharmaceutical Industry

  • Clerico, Giuseppe (1994), ‘Raccolta e allocazione di sangue: donazione, mercato e intervento pubblico (Gathering and allocation of blood: gift, market and public intervention)’, 4 Rassegna giuridica della sanitˆ , 140-152.
  • Elhauge, Einer Richard (1996), ‘The Limited Potential of Medical Technology Assessment’, Virginia Law Review .
  • Hertig, Gerard (1994), ‘Imperfect Mutual Recognition for EC Financial Services’, 14 International Review of Law and Economics , 177-186.
  • Kitch, Edmund W. (1973), ‘The Patent System and the New Drug Application: An Evaluation of the Incentives for Private Investment in New Drug Research and Marketing’, in Landau (ed.), Regulating New Drugs , University of Chicago Center for Policy Study.
  • Kitch, Edmund W. (1980), ‘The Political Economy of Innovation in Drugs and Drug Regulation Reform’, in Helms, Robert B. (ed.), The International Supply of Medicines: Implications of U.S. Regulatory Reform , Washington, American Enterprise Institute for Public Policy Research.
  • Kitch, Edmund W. (1986), ‘The Vaccine Dilemma’, 2 Issues in Science and Technology , 108 ff.
  • Kitch, Edmund W. (1988), ‘American Law and Preventive Vaccination Programs’, in Plotkin, Stanley A. and Mortimer, Edward A. (eds.), Vaccines , Philadelphia, W.B. Saunders Company, 612 ff.
  • Kitch, Edmund W. and Mortimer, Edward A., Jr. (1994), ‘American Law, Preventive Vaccine Programs, and the National Vaccine Injury Compensation Program’, in Plotkin, Stanley A. and Mortimer, Edward A. (eds.), Vaccines , Philadelphia, W.B. Saunders Company, 93 ff.
  • MacKaay, Ejan (1992), ‘Penser l’informatique gŽnŽtique en droit quŽbŽcois (Thinking about Genetic Computing in Quebec Law)’, in Knoppers, Bartha Maria, Cadiet, Lo•c and Laberge, Claude M. (eds.), La gŽnŽtique humaine: de l’information ˆ l’informatisation [Human Genetics: From Information to Computerization] , MontrŽal et Paris, ThŽmis et LITEC, 25-38.
  • Mariner, Wendy K. (1985), ‘The Potential Impact of Pharmaceutical and Vaccine Litigation’, in Baily, Mary Ann and Cikins, Warren I. (eds.), The Effects of Litigation on Health Care Costs , Washington, Brookings Institution, 43-68.
  • Peltzman, Sam (1973), ‘The Benefits and Costs of New Drug Regulation’, in Landan, Richard (ed.), Regulating New Drugs , University of Chicago Center for Policy Study.
  • Peltzman, Sam (1975), Regulation of Pharmaceutical Innovation , Washington, American Enterprise Institute for Public Policy Research, 118 p.
  • Peltzman, Sam (1975), ‘The 1962 Drug Amendments: Reply’, Journal of Political Economy .
  • Peltzman, Sam (1975), ‘The Diffusion of Pharmaceutical Innovation’, in Helms, Robert B., Drug Development and Marketing , American Enterprise Institute Press.
  • Peltzman, Sam (1977), ‘The Effects of Regulation and New Drugs’, in Siegan, Bernard H. (ed.), The Interactions of Economics and the Law , Lexington (MA), Lexington Books.
  • Peltzman, Sam (1987), ‘By Prescription Only’, 11(3-4) Regulation , 23-28.
  • Peltzman, Sam (1987), ‘The Health Effects of Mandatory Prescriptions’, 30 Journal of Law and Economics , 207-238.
  • Peltzman, Sam (1987), ‘Regulation and Health: The Case of Mandatory Prescriptions and an Extension’, March Managerial and Decision Economics .
  • Peltzman, Sam (1987), ‘By Prescription Only’, ² Regulation .
  • Rapp, Richard Tilden and Lloyd, Adam (1994), ”Civilized’ Pharmaceutical Price Regulation: Can the U.S. Have It Too?’, 17(2) Regulation , 72-82.
  • Rapp, Richard Tilden and Rozek, Richard P. (1992), ‘Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation’, 7 Journal of Economic Integration , 181-203.
  • Rubin, Paul H. (1994), ‘Are Pharmaceutical Ads Deceptive?’, Food and Drug Law Journal , 7-21.
  • Temin, Peter (1992), ‘Realized Benefits from Switching Drugs’, 35 Journal of Law and Economics , 351-369.
Copied to clipboard